Loading company
Minerva Neurosciences, Inc.
NERV · Nasdaq · ·
Next earnings: November 4, 2026
$3.36-1.2%Sep 29 close
- 1M
- -30.6%
- 6M
- -43.7%
- 1Y
- +59.6%
- 5Y
- -79.2%
NERV · Nasdaq · ·
Next earnings: November 4, 2026
$3.36-1.2%Sep 29 close
Minerva Neurosciences, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2021, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2021 | 3 months toDec 31, 2020 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | $17.5M | -$3.3M | +636.01% |
| Profit per share | $0.22 | -$0.43 | +151.35% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Minerva Neurosciences, Inc. has no earnings call transcript available.
“The psychiatry field has increasingly recognized negative symptoms as a distinct, undertreated driver of disability in schizophrenia, separate from the positive symptoms that current antipsychotics are designed to address,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Minerva Neurosciences, Inc.’s Item 2.02 8-K filed August 7, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.